Diabetic nephropathy: Are there new and potentially promising therapies targeting oxygen biology?

Kidney International

Volumn 84, Issue 4, 2013, Pages 693-702

  Miyata, Toshio ^a   Suzuki, Norio ^a   Van Ypersele De Strihou, Charles ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

allosteric effector; fibrosis; Keap1 Nrf2 pathway; PAI 1; PHD HIF pathway; REP cell

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT; BARDOXOLONE METHYL; DISUFENTON SODIUM; ENZYME INHIBITOR; ERYTHROPOIETIN; FG 4592; FIBRIC ACID DERIVATIVE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1 INHIBITOR; MYOINOSITOL HEXAKISPHOSPHATE HEXASODIUM SALT; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 1 INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 2 INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; PROLYLHYDROXYLASE 1; PROLYLHYDROXYLASE 2; PROLYLHYDROXYLASE 3; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; SULFORAPHANE; TM 6008; TM 6089; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CARDIORENAL ANEMIA SYNDROME; CELL FUNCTION; CELL HYPOXIA; CELL MATURATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CELL TYPE; CHRONIC KIDNEY DISEASE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIALYSIS; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; DYSERYTHROPOIESIS; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOXEMIA; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LIPOLYSIS; MUSCLE SPASM; MYOFIBROBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RENAL ERYTHROPOIETIN PRODUCING CELL; REVIEW; SIDE EFFECT; UREMIA; WEIGHT REDUCTION;

ANOXIA; DIABETIC NEPHROPATHIES; ERYTHROPOIETIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; OXYGEN; SIGNAL TRANSDUCTION;

EID: 84885318238     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.74     Document Type: Review

References (120)

1. Kulkarni AC, Kuppusamy P, Parinandi N. Oxygen, the lead actor in the pathophysiologic drama: enactment of the trinity of normoxia, hypoxia, and hyperoxia in disease and therapy. Antioxid Redox Signal 2007; 9: 1717-1730.
2. Wu H, Liu X, Jaenisch R et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
3. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011; 589: 1251-1258.
4. Obara N, Suzuki N, Kim K et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008; 111: 5223-5232.
5. Maxwell PH, Ferguson DJ, Nicholls LG et al. The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int 1997; 52: 715-724.
6. Asada N, Takase M, Nakamura J et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011; 121: 3981-3990.
7. Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
8. Jennings PE, Chirico S, Jones AF et al. Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 1987; 6: 151-154.
9. Suzuki E, Yasuda K, Takeda N et al. Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 1992; 18: 153-158.
10. Bravi MC, Pietrangeli P, Laurenti O et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997; 46: 1194-1198.
11. Wells-Knecht MC, Lyons TJ, McCance DR et al. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 1997; 100: 839-846.
12. Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
13. Suzuki D, Miyata T, Saotome N et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10: 822-832.
14. Uchida K, Kanematsu M, Sakai K et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 1998; 95: 4882-4887.
15. Pennathur S, Wagner JD, Leeuwenburgh C et al. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107: 853-860.
16. Shah SV, Baliga R, Rajapurkar M et al. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28.
17. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
18. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998; 54: 775-784.
19. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
20. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001; 107: 799-801.
21. Gorin Y, Block K, Hernandez J et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280: 39616-39626.
22. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007; 27: 130-143.
23. Aragonés J, Schneider M, Van Geyte K et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008; 40: 170-180.
24. Miyata T, Kikuchi K, Kiyomoto H et al. New era for drug discovery and development in renal disease. Nat Rev Nephrol 2011; 7: 469-477.
25. Ries M, Basseau F, Tyndal B et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging 2003; 17: 104-113.
26. Rosenberger C, Rosen S, Shina A et al. Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int 2006; 70: 60-70.
27. Tanaka T, Miyata T, Inagi R et al. Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 2004; 165: 1979-1992.
28. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
29. Palm F, Friederich M, Carlsson PO et al. Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: implications for renomedullary oxygen availability. Am J Physiol Renal Physiol 2008; 294: F30-F37.
30. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268.
31. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18: 15-20.
32. Miyata T, de Strihou CY. Diabetic nephropathy: a disorder of oxygen metabolism? Nat Rev Nephrol 2010; 6: 83-95.
33. Garcia Soriano F, Virág L, Jagtap P et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-113.
34. Du X, Matsumura T, Edelstein D et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-1057.
35. Prabhakar S, Starnes J, Shi S et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18: 2945-2952.
36. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
37. Miyata T, Kurokawa K, Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744-1752.
38. Miyata T, Kurokawa K, van Ypersele de Strihou C. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy: a detective story (review). Curr Drug Target 2005; 5: 323-329.
39. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115: 2656-2664.
40. Lindenmeyer MT, Rastaldi MP, Ikehata M et al. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol 2008; 19: 2225-2236.
41. Zhang F, Gagnon RF, Richards GK et al. Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin. Nephron 1996; 72: 654-661.
42. Ataka K, Maruyama H, Neichi T et al. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 2003; 23: 315-323.
43. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 2012; 318: 1068-1073.
44. Righetti M. Cardio-renal-anemia syndrome: a link between erythropoietin, dimethylarginine and homocysteine. Curr Med Chem 2012; 19: 3502-3507.
45. Suzuki N, Ohneda O, Takahashi S et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100: 2279-2288.
46. Suzuki N, Obara N, Yamamoto M. Use of gene-manipulated mice in the study of erythropoietin gene expression. Methods Enzymol 2007; 435: 157-177.
47. Noguchi CT, Wang L, Rogers HM et al. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008; 10: e36.
48. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
49. Marx J. How cells endure low oxygen. Science 2004; 303: 1454-1456.
50. Epstein AC, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
51. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-354.
52. Ivan M, Kondo K, Yang H et al. HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468.
53. Hon WC, Wilson MI, Harlos K et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417: 975-978.
54. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
55. Ohh M, Park CW, Ivan M et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-427.
56. Eguchi H, Ikuta T, Tachibana T et al. A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxiainducible factor 1beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. J Biol Chem 1997; 272: 17640-17647.
57. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402.
58. Takeda K, Aguila HL, Parikh NS et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111: 3229-3235.
59. Percy MJ, Furlow PW, Lucas GS et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358: 162-168.
60. Bernhardt WM, Wiesener MS, Weidemann A et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170: 830-842.
61. Kojima I, Tanaka T, Inagi R et al. Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol 2007; 18: 1218-1226.
62. Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 2009; 8: 139-152.
63. Salnikow K, Donald SP, Bruick RK et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279: 40337-40344.
64. Smith EL. Presence of cobalt in the anti-pernicious anaemia factor. Nature 1948; 162: 144.
65. Berk L, Burchenal JH, Castle WB. Erythropoietic effect of cobalt in patients with or without anemia. N Engl J Med 1949; 240: 754-761.
66. Edwards MS, Curtis JR. Use of cobaltous chloride in anaemia of maintenance hemodialysis patients. Lancet 1971; 2: 582-583.
67. Metzen E, Berchner-Pfannschmidt U, Stengel P et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 2003; 116: 1319-1326.
68. Steinhoff A, Pientka FK, Mö ckel S et al. Cellular oxygen sensing: importins and exportins are mediators of intracellular localisation of prolyl-4-hydroxylases PHD1 and PHD2. Biochem Biophys Res Commun 2009; 387: 705-711.
69. Berchner-Pfannschmidt U, Tug S, Trinidad B et al. Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide. J Biol Chem 2008; 283: 31745-31753.
70. Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 2008; 15: 635-641.
71. Berchner-Pfannschmidt U, Yamac H, Trinidad B et al. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem 2007; 282: 1788-1796.
72. Tug S, Delos Reyes B, Fandrey J et al. Non-hypoxic activation of the negative regulatory feedback loop of prolyl-hydroxylase oxygen sensors. Biochem Biophys Res Commun 2009; 384: 519-523.
73. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003; 43: 233-260.
74. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2 Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005; 7: 385-394.
75. Cho HY, Jedlicka AE, Reddy SP et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002; 26: 175-182.
76. Cho HY, Reddy SP, Yamamoto M et al. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004; 18: 1258-1260.
77. Shih AY, Li P, Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 2005; 25: 10321-10335.
78. Leonard MO, Kieran NE, Howell K et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 2006; 20: 2624-2626.
79. Liu M, Grigoryev DN, Crow MT et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76: 277-285.
80. Yoh K, Hirayama A, Ishizaki K et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008; 13: 1159-1170.
81. Itoh K, Wakabayashi N, Katoh Y et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
82. Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-245.
83. Miyata T, Takizawa S, van Ypersele de Strihou C. Hypoxia.Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets. Am J Physiol Cell Physiol 2011; 300: C226-C231.
84. Okada K, Shoda J, Taguchi K et al. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem Biophys Res Commun 2009; 389: 431-436.
85. Pan X, Suzuki N, Hirano I et al. Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PLoS One 2011; 6: e25839.
86. Maxwell PH, Osmond MK, Pugh CW et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44: 1149-1162.
87. Koury ST, Koury MJ, Bondurant MC et al. Quantitation of erythropoietinproducing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989; 74: 645-651.
88. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925.
89. Inoue T, Takenaka T, Hayashi M et al. Fibroblast expression of an IkB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol 2010; 21: 2047-2052.
90. Ivan M, Haberberger T, Gervasi DC et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002; 99: 13459-13464.
91. McDonough MA, McNeill LA, Tilliet M et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 2005; 127: 7680-7681.
92. Hill P, Shukla D, Tran MG et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2008; 19: 39-46.
93. Nangaku M, Izuhara Y, Takizawa S et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007; 27: 2548-2554.
94. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-792.
95. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007; 116: 774-781.
96. Mazzone M, Dettori D, Leite de Oliveira R et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-851.
97. Loinard C, Ginouvès A, Vilar J et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 2009; 120: 50-59.
98. Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 2012; 4: 830-845.
99. Minamishima YA, Moslehi J, Bardeesy N et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008; 111: 3236-3244.
100. Ladroue C, Carcenac R, Leporrier M et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359: 2685-2692.
101. Siddiq A, Aminova LR, Troy CM et al. Selective inhibition of hypoxiainducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-a and CREB-independent pathways. J Neurosci 2009; 29: 8828-8838.
102. Zhou F, Zhu X, Castellani RJ et al. Hibernation, a model of neuroprotection. Am J Pathol 2001; 158: 2145-2151.
103. Drew KL, Harris MB, LaManna JC et al. Hypoxia tolerance in mammalian heterotherms. J Exp Biol 2004; 207: 3155-3162.
104. Fylaktakidou KC, Lehn JM, Greferath R et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett 2005; 15: 1605-1608.
105. Bunn HF, Jandl JH. Control of hemoglobin function within the red cell. N Engl J Med 1970; 282: 1414-1421.
106. Bersin RM, Kwasman M, Lau D et al. Importance of oxygen-hemoglobin binding to oxygen transport in congestive heart failure. Br Heart J 1993; 70: 443-447.
107. Teisseire B, Ropars C, Villeré al MC et al. Long-term physiological effects of enhanced O2 release by inositol hexaphosphate-loaded erythrocytes. Proc Natl Acad Sci USA 1987; 84: 6894-6898.
108. Biolo A, Greferath R, Siwik DA et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Proc Natl Acad Sci USA 2009; 106: 1926-1929.
109. Aprahamian M, Bour G, Akladios CY et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1a suppression and eradication of early hepatoma tumors in rats. Chembiochem 2011; 12: 777-783.
110. Sihn G, Walter T, Klein JC et al. Anti-angiogenic properties of myoinositol trispyrophosphate in ovo and growth reduction of implanted glioma. FEBS Lett 2007; 581: 962-966.
111. Shuaib A, Lees KR, Lyden P et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-571.
112. Bath PM, Gray LJ, Bath AJ et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009; 157: 1157-1171.
113. Dinkova-Kostova AT, Liby KT, Stephenson KK et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005; 102: 4584-4589.
114. Yoh K, Itoh K, Enomoto A et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001; 60: 1343-1353.
115. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
116. Ping Z, Liu W, Kang Z et al. Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain Res 2010; 1343: 178-185.
117. Zheng H, Whitman SA, Wu W et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011; 60: 3055-3066.
118. Tong KI, Kobayashi A, Katsuoka F et al. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 2006; 387: 1311-1320.
119. Suzuki N, Obara N, Pan X et al. Specific contribution of the erythropoietin gene 30 enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol 2011; 31: 3896-3905.
120. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010; 329: 407.